Ascendis Pharma AS (A71) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ascendis Pharma AS (A71) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.72 Million ≈ $-9.03 Million USD) by net assets (€487.97 Million ≈ $570.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ascendis Pharma AS balance sheet quality to measure how much of total assets are equity-financed.
Ascendis Pharma AS - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Ascendis Pharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ascendis Pharma AS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Ascendis Pharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascendis Pharma AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rocket Companies Inc
NYSE:RKT
|
0.080x |
|
Bollore SA
PA:BOL
|
0.000x |
|
Permian Resources Corporation
NYSE:PR
|
0.068x |
|
Gaming & Leisure Properties
NASDAQ:GLPI
|
0.048x |
|
Gold Circuit Electronics Ltd
TW:2368
|
0.144x |
|
Equity Lifestyle Properties Inc
NYSE:ELS
|
0.107x |
|
TransUnion
NYSE:TRU
|
0.017x |
|
Penumbra Inc
NYSE:PEN
|
0.059x |
Annual Cash Flow Conversion Efficiency for Ascendis Pharma AS (2016–2025)
The table below shows the annual cash flow conversion efficiency of Ascendis Pharma AS from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Ascendis Pharma AS market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-162.82 Million ≈ $-190.35 Million |
€53.90 Million ≈ $63.01 Million |
-0.331x | -111.43% |
| 2024-12-31 | €-105.71 Million ≈ $-123.58 Million |
€-306.20 Million ≈ $-357.98 Million |
2.897x | -9.70% |
| 2023-12-31 | €-145.70 Million ≈ $-170.34 Million |
€-467.36 Million ≈ $-546.39 Million |
3.208x | +270.42% |
| 2022-12-31 | €263.35 Million ≈ $307.88 Million |
€-495.70 Million ≈ $-579.52 Million |
-1.882x | -298.24% |
| 2021-12-31 | €883.63 Million ≈ $1.03 Billion |
€-417.65 Million ≈ $-488.28 Million |
-0.473x | -45.98% |
| 2020-12-31 | €838.71 Million ≈ $980.54 Million |
€-271.55 Million ≈ $-317.47 Million |
-0.324x | -9.88% |
| 2019-12-31 | €597.11 Million ≈ $698.09 Million |
€-175.94 Million ≈ $-205.69 Million |
-0.295x | +40.55% |
| 2018-12-31 | €280.05 Million ≈ $327.41 Million |
€-138.80 Million ≈ $-162.27 Million |
-0.496x | +2.43% |
| 2017-12-31 | €187.21 Million ≈ $218.87 Million |
€-95.10 Million ≈ $-111.18 Million |
-0.508x | -49.08% |
| 2016-12-31 | €176.61 Million ≈ $206.48 Million |
€-60.18 Million ≈ $-70.36 Million |
-0.341x | -- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more